Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes
Bio€quity hosts Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. Ilya Pharma will share milestones and data from the clinical developments and the emerging pipeline.
Patent covers treatment of cutaneous human and animal wounds using transformed lactic acid bacteria
Bloomberg reports: EU will become shareholder in startups for the first time.
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.